SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter 2 (SGLT2) inhibitors had been frequently administered for T2DM treatment recently with glycolated hemoglobin retardation from 0.5 to 1.0 percent 4, 5.